Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis

REFERENCES

• American Academy of Ophthalmology. Preferred Practice Pattern: Blepharitis. September 2013 revision. Available at: http://one.aao.org/preferred-practice-pattern/blepharitis-ppp–2013. Accessed February 2, 2015.
   Google Scholar
• Lindsley K, Matsumura S, Hatef E, et al. Interventions for chronic blepharitis. Cochrane Database Syst Rev. 2012;5:CD005556.
   PubMed Web of Science ®Google Scholar
• Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009;7(2 suppl):S1–14.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Karpecki PM, Perez VL. Treatment of blepharitis: recent clinical trials. Ocul Surf. 2014;12(4):273–284.
   PubMed Web of Science ®Google Scholar
• Nemet AY, Vinker S, Kaiserman I. Associated morbidity of blepharitis. Ophthalmology. 2011;118(6):1062–1068.
   PubMed Web of Science ®Google Scholar
• Chiang CC, Lin CL, Tsai YY, et al. Patients with blepharitis are at elevated risk of anxiety and depression. PLoS One. 2013;8(12): e83335.
   Web of Science ®Google Scholar
• Comstock TL, Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. 2012;2012:789623.
   PubMedGoogle Scholar
• Tobradex (tobramycin and dexamethasone ophthalmic suspension) prescribing information. Fort Worth, TX: Alcon Laboratories, February; 2009.
   Google Scholar
• Zylet (package insert). Tampa, FL: Bausch & Lomb Inc; 2013.
   Google Scholar
• White EM, Macy JI, Bateman KM, et al. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin. 2008;24(1):287–296.
   PubMed Web of Science ®Google Scholar
• Chen M, Gong L, Sun X, et al. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Curr Med Res Opin. 2012;28(3):385–394.
   PubMed Web of Science ®Google Scholar
• ICH Expert Working Group. Harmonised Tripartite Guideline E6. Guideline for Good Clinical Practice. London: ICH; 2002.
   Google Scholar
• World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. Ferney-Vottaire, France: World Medical Association; 1964.
   Google Scholar
• Rhee SS, Mah FS. Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharokeratoconjunctivitis. Adv Ther. 2007;24:60–67.
   PubMed Web of Science ®Google Scholar
• Belfort Jr R, Gabriel L, Martins Bispo PJ, et al. Safety and efficacy of moxifloxacin-dexamethasone eyedrops as treatment for bacterial ocular infection associated with bacterial blepharitis. Adv Ther. 2012;29:416–426.
   PubMed Web of Science ®Google Scholar
• Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70:482–491.
   PubMed Web of Science ®Google Scholar
• Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol. 1963;70:500–507.
   PubMed Web of Science ®Google Scholar
• Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol. 1963;70:492–499.
   PubMedGoogle Scholar
• Podos SM, Becker B, Morfton WR. High myopia and primary open-angle glaucoma. Am J Ophthalmol. 1966;62:1039–1043.
   Web of Science ®Google Scholar
• Chang DF, Tan JJ, Tripodis Y. Risk factors for steroid response among cataract patients. J Cataract Refract Surg. 2011;37:675–681.
   PubMed Web of Science ®Google Scholar
• Cho H-K, Kee C. Population-based glaucoma prevalence studies in Asians. Surv Ophthalmol. 2014;59:434–447.
   PubMed Web of Science ®Google Scholar
• Doss EL, Doss L, Han Y, et al. Risk factors for glaucoma suspicion in healthy young Asian and Caucasian Americans. J Ophthalmol. 2014;2014:726760.
   Google Scholar
• Wen G, Tarczy-Hornoch K, McKean-Cowdin R, et al. Prevalence of myopia, hyperopia and astigmatism in non-Hispanic white and Asian children: multi-ethnic pediatric eye disease study. Ophthalmology. 2013;120:2109–2116.
   PubMed Web of Science ®Google Scholar
• Leung CK, Palmiero P-M, Weinreb RN, et al. Comparisons of anterior segment biometry between Chinese and Caucasians using anterior segment optical coherence tomography. Br J Ophthalmol. 2010;94:1184–1189.
   PubMed Web of Science ®Google Scholar
• Shukla D, Vidhya N, Prasad NM, et al. Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone. Am J Ophthalmol. 2007;144(3):453–454.
   PubMed Web of Science ®Google Scholar
• Kim NR, Kim CY, Kim H, et al. Comparison of Goldmann applanation tonometer, noncontact tonometer, and TonoPen XL for intraocular pressure measurement in different types of glaucomatous, ocular hypertensive, and normal eyes. Curr Eye Res. 2011;36:295–300.
   PubMed Web of Science ®Google Scholar
• Farhood QK. Comparative evaluation of intraocular pressure with an air-puff tonometer versus a Goldmann applanation tonometer. Clin Ophthalmol. 2013;7:23–27.
   PubMedGoogle Scholar
• Yilmaz I, Altan C, Aygit ED, et al. Comparison of three methods of tonometry in normal subjects: Goldmann applanation tonometer, non-contact airpuff tonometer, and Tono-Pen XL. Clin Ophthalmol. 2014;8:1069–1074.
   PubMedGoogle Scholar
• Parker VA, Herrtage J, Sarkies NJ. Clinical comparison of the Keeler Pulsair 3000 with Goldmann applanation tonometry. Br J Ophthalmol. 2001;85:1303–1304.
   PubMed Web of Science ®Google Scholar
• Johannesson G, Hallberg P, Eklund A, et al. Pascal, ICare and Goldmann applanation tonometry–a comparative study. Acta Ophthalmol. 2008;86(6):614–621.
   PubMed Web of Science ®Google Scholar
• Wang AS, Alencar LM, Weinreb RN, et al. Repeatability and reproducibility of Goldmann applanation, dynamic contour, and ocular response analyzer tonometry. J Glaucoma. 2013;22(2):127–132.
   PubMed Web of Science ®Google Scholar
• Sullivan-Mee M, Gerhardt G, Halverson KD, et al. Repeatability and reproducibility for intraocular pressure measurement by dynamic contour, ocular response analyzer, and goldmann applanation tonometry. J Glaucoma. 2009;18(9):666–673.
   PubMed Web of Science ®Google Scholar
• Kaufmann C, Bachmann LM, Thiel MA. Comparison of dynamic contour tonometry with goldmann applanation tonometry. Invest Ophthalmol Vis Sci. 2004;45(9):3118–3121.
   PubMed Web of Science ®Google Scholar
• Kotecha A, White ET, Shewry JM, et al. The relative effects of corneal thickness and age on Goldmann applanation tonometry and dynamic contour tonometry. Br J Ophthalmol. 2005;89(12):1572–1575.
   PubMed Web of Science ®Google Scholar
• Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res. 1991;10(10):933–937.
   PubMed Web of Science ®Google Scholar
• Bodor N, Loftsson T, Wu WM. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res. 1992;9:1275–1278.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Bartlett JD, Paterno MR, et al. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea. 2008;27(1):50–55.
   PubMed Web of Science ®Google Scholar
• Bartlett JD, Horwitz B, Laibovitz R, et al. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol. 1993;9:157–165.
   PubMedGoogle Scholar
• The Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol. 1999;127:537–544.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444–457.
   PubMed Web of Science ®Google Scholar
• Lee H, Chung B, Kim KS, et al. Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial. Am J Ophthalmol. 2014;158(6): 1172–1183.e1.
   Web of Science ®Google Scholar
• Novack GD, Howes RS, Crockett RS, et al. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma. 1998;7:266–269.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Djalilian AR, Sanderson JP. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea. 2009;28:1139–1143.
   PubMed Web of Science ®Google Scholar
• Lane SS, Holland EJ. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg. 2013;39:168–173.
   PubMed Web of Science ®Google Scholar
• Thanathanee O, Sriphon P, Anutarapongpan O, et al. A randomized controlled trial comparing dexamethasone with loteprednol etabonate on postoperative photorefractive keratectomy. J Ocul Pharmacol Ther. 2015;31:165–168.
   PubMed Web of Science ®Google Scholar